EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers

Dasohm Kim iD, Minkyu Choi iD, Byung Hak Jin iD, Taegon Hong iD, Choon Ok Kim iD, Byung Won Yoo iD, Min Soo Park iD

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13566 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Dasohm Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evogliptin (EV) is a novel dipeptidyl peptidase‐4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter‐2 inhibitors (SGLT2i) in healthy volunteers since combination therapy of DPP4i and SGLT2i has been considered as an effective option for T2DM treatment. A randomized, open‐label, multiple‐dose, two‐arm, three‐period, three treatments, two‐sequence crossover study was conducted in healthy Korean volunteers. In arm 1, subjects were administered 5 mg of EV once daily for 7 days, 25 mg of empagliflozin (EP) once daily for 5 days, and the combination once daily for 5 days (EV + EP). In arm 2, subjects were administered 5 mg of EV once daily for 7 days, 10 mg of dapagliflozin (DP) once daily for 5 days, and the combination once daily for 5 days (EV + DP). Serial blood samples were collected for PK analysis, and oral glucose tolerance tests were conducted for PD analysis. In each arm, a total of 18 subjects completed the study. All adverse events (AEs) were mild with no serious AEs. The geometric mean ratio and confidence interval of the main PK parameters (maximum concentration of the drug in plasma at steady state and area under the plasma drug concentration‐time curve within a dosing interval at a steady state) between EV and either EP or DP alone were not significantly altered by co‐administration. Administration of EV + EP or EV + DP did not result in significant PD changes, as determined by the glucose‐lowering effect. Administration of EV + EP or EV + DP had no significant effects on the PK profiles of each drug. All treatments were well‐tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHumansMaleHealthy VolunteersCross-Over StudiesHypoglycemic AgentsDrug InteractionsBenzhydryl CompoundsGlucosidesPiperazines

Substanzen

Hypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsempagliflozinBenzhydryl CompoundsGlucosidesdapagliflozin4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-onePiperazines

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pharmaceutical Medicine and Regulatory Sciences, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, South Korea.
  • Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.

ORCID-Profile: Dasohm Kim, Minkyu Choi, Byung Hak Jin, Taegon Hong, Choon Ok Kim, Byung Won Yoo, Min Soo Park

Zitieren

APA

Kim, D., Choi, M., Jin, B. H., Hong, T., Kim, C. O., Yoo, B. W., & Park, M. S. (2023). Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers. Clinical and Translational Science. https://doi.org/10.1111/cts.13566

Vancouver

Kim D, Choi M, Jin BH, Hong T, Kim CO, Yoo BW, et al. Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers. Clinical and Translational Science. 2023. doi:10.1111/cts.13566

BibTeX
@article{Kim2023,
  author = {Kim, Dasohm and Choi, Minkyu and Jin, Byung Hak and Hong, Taegon and Kim, Choon Ok and Yoo, Byung Won and Park, Min Soo},
  title = {Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13566}
}
Kostenlos starten →